Add-On Homeopathy Linked to Better Quality of Life and Longer Survival in Advanced Lung Cancer Trial

A controversial clinical trial has once again thrust homeopathy into the center of a scientific firestorm. In a prospective, randomized, placebo-controlled, double-blind, three-arm, multicenter phase III study published in Supportive Care in Cancer, researchers led by Michael Frass of the Medical University of Vienna report that patients with advanced non-small cell lung cancer (NSCLC) who received individualized homeopathic treatment as an add-on to conventional chemotherapy experienced significantly better quality of life and lived longer than patients who received placebo. The findings, based on the same trial dataset as a 2020 report that was retracted by The Oncologist in November 2025, arrive with an unusual methodological pedigree: a quadruple-checked data analysis process in which study design, data entry, data clearing, and statistical evaluation were performed in four mutually independent steps.

The trial enrolled 158 patients with stage IV NSCLC of European ancestry between February 2012 and July 2017 across four Austrian outpatient centers. Of these, 52 patients declined randomization but consented to observation as an untreated control group, while 106 were randomized. Eight randomized patients were excluded because of sensitizing EGFR mutations or ALK translocations reported immediately after randomization, leaving 98 patients in the double-blind comparison: 51 received individualized homeopathic medicinal products (HMPs) and 47 received placebo. All patients concurrently received standard conventional oncological treatment, typically cisplatin-based chemotherapy combined with gemcitabine or pemetrexed.

The homeopathic intervention was deeply individualized. At study entry, each patient underwent a detailed homeopathic case history lasting approximately 60 minutes, in which physical, mental, and emotional symptoms were recorded in totality. Homeopathic physicians then repertorized the symptom profile, matching it to remedies prepared from plant, mineral, or animal sources at decimal, centesimal, or quinquaginta millesimal (Q) potencies. Liquid Q-potencies were administered in ascending series from Q1 toward Q30, with patients instructed to dilute and succuss the preparation daily. Sugar granules at D-, C-, and LM-potencies served as constitutional medication. The Maria Treu Pharmacy in Vienna prepared both verum and placebo, which were visually identical and dispatched by mail in neutral wrapping to maintain the double-blind design.

Quality of life was assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30), the 36-item Short-Form Health Survey (SF-36), and a visual analogue scale for subjective well-being, completed at baseline, 9 weeks, and 18 weeks. The results were striking. Global health status was significantly higher in the homeopathy group than in the placebo group at both 9 weeks and 18 weeks (p < 0.001). With the exception of cognitive functioning at 9 weeks and pain, diarrhea, and financial difficulties at 9 weeks, all functional and symptom scales favored the homeopathy group, with between-group differences exceeding the 10-point threshold generally regarded as clinically meaningful. Multivariate analysis revealed significant time effects, group effects, and time-by-group interactions (p < 0.001), indicating that scores improved over time in the homeopathy group while deteriorating in the placebo group.

Survival outcomes were equally provocative. Over the 730-day observation period, median survival time was 435 days in the homeopathy group, 257 days in the placebo group (p = 0.010), and 228 days in the non-randomized control group (p < 0.001). The corresponding 2-year survival rates were 45.1 percent, 23.4 percent, and 13.5 percent, respectively. The difference between the homeopathy and placebo groups was statistically significant (p = 0.020), as was the difference between homeopathy and control (p < 0.001). Notably, the difference between the placebo group and the non-randomized control group was not statistically significant (p = 0.154). An independent physician confirmed that all deaths were directly attributable to the underlying cancer, and no adverse effects were reported in any group.

The publication history of this dataset is anything but straightforward. The earlier report of the same trial, published in The Oncologist in 2020, was corrected in 2021, received an Expression of Concern in 2022 following a request by the Commission for Research Integrity of the Austrian Agency for Scientific Integrity, was corrected a second time in 2024, and was finally retracted by the journal in November 2025. The retraction notice stated that the journal no longer had confidence in the results and conclusions; nine co-authors disagreed with the decision, one agreed, and the remaining authors did not comment. The present article explicitly discloses this history so that readers can judge the provenance of the data. The authors emphasize that the new publication is not a reprint but a deliberately redesigned analysis intended to enhance methodological transparency, with reporting following the CONSORT statement and interpretations anchored conservatively in published thresholds for clinically meaningful change.

A central interpretive challenge is the whole-systems nature of the intervention. Both randomized groups received an identical package of homeopathic care: the same homeopathic physicians, consultations of the same length and frequency, the same individualized prescribing process, and the same daily preparation ritual. The two groups differed exclusively in whether the dispensed preparation was the individually selected HMP or an indistinguishable placebo. The comparison of homeopathy versus placebo therefore isolates the contribution of the remedy within the context of homeopathic care, but it cannot quantify the contribution of the consultation itself. Conversely, the comparison with the non-randomized control group, which received no homeopathic consultation at all, reflects the effect of the entire package together with selection effects and must not be read as an effect of the HMP.

The authors draw a conceptual parallel to the landmark palliative care trial by Temel and colleagues, which demonstrated that early integration of palliative care with standard oncological care prolonged median survival in metastatic NSCLC patients despite less aggressive end-of-life care. They also cite the recent IMPROVE trial, which reported that a digitally delivered integrative medicine intervention combining exercise and mind-body therapies improved overall survival in patients with solid tumors receiving systemic therapy. These parallels suggest that interventions addressing symptom burden and overall well-being may independently contribute to survival, possibly through improved treatment tolerance, reduced psychological distress, or enhanced immune function. However, the biological plausibility of highly diluted homeopathic preparations remains a subject of intense scientific debate, and the mechanisms by which such preparations could influence tumor biology or host defense are not established.

Several limitations temper the findings. QoL was assessed only up to 18 weeks, so no conclusions can be drawn about quality-of-life trajectories beyond this window, particularly in the terminal phase. Attrition was substantial and differed between the randomized groups: 46 of 51 patients in the homeopathy group but only 33 of 47 in the placebo group attended the third visit, due to higher mortality in the placebo group. This differential dropout could have introduced attrition bias and potentially contributed to an overestimation of the between-group difference. The control group was not randomized, precluding causal interpretation of comparisons involving it. The subjective well-being questionnaire was developed by one of the authors without formal validation. Additionally, conventional therapy during the study period predated the widespread adoption of immune checkpoint inhibitors, and further studies within contemporary immuno-oncological regimens are necessary.

The authors propose that add-on homeopathy may serve as a low-risk, low-cost supportive care option delivered strictly as an adjunct to, not a replacement for, evidence-based conventional treatment. They call for independent replication by research groups without prior involvement in homeopathy research, confirmation within current standard-of-care regimens including immune checkpoint inhibitors, larger sample sizes with adequate power for survival as a primary endpoint, extended quality-of-life follow-up through the end-of-life period, and health economic evaluation. Until such replication occurs, the findings remain associations observed in a single trial with a secondary survival endpoint and a non-randomized control group subject to selection bias. The study was registered at ClinicalTrials.gov (NCT01509612) and supported by the Institute for Homeopathic Research, Vienna.

Subject of Research: homeopathy in lung cancer

Article Title: Improved quality of life and prolonged survival with add-on homeopathic treatment in patients with non-small cell lung cancer: a prospective, randomized, placebo-controlled, double-blind, three-arm, multicenter study

Article References: Frass, M., Lechleitner, P., Gründling, C., Gaertner, K., Duscheck, C., Muchitsch, I., Manchanda, R. K., & Burghuber, O. C. (2026). Improved quality of life and prolonged survival with add-on homeopathic treatment in patients with non-small cell lung cancer: a prospective, randomized, placebo-controlled, double-blind, three-arm, multicenter study. Supportive Care in Cancer, 34(10), Article 952. https://doi.org/10.1007/s00520-026-11154-3

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11154-3

Keywords: homeopathy, lung cancer, NSCLC, quality of life, survival, clinical trial, placebo-controlled, complementary medicine, supportive care, oncology, EORTC QLQ-C30, retraction